Contents

Search


rifamycin (rifamycin SV, Rifocin, Aemcolo)

Occurrence: - natural antibiotic of group of antibiotics produced by Streptpmyces mediterranei (Amycolatopsis mediterranei) Pharmacology: Indications: - treatment of autoimmune disorders - rheumatoid arthritis - bacterial infections due to susceptible organisms - mycobacterial infections - tuberculosis - pulmonary tuberculosis - latent tuberculosis - tuberculous meningitis - leprosy - brucellosis - osteomyelitis - anthrax - cutaneous anthrax - inhalation anthrax - traveler's diarrhea (Aemcolo) [5] - hepatic encephalopathy Monitor: - liver function tests & CBC monthly Antimicrobial activity: - Gram-positive & Gram-negative bacteria - used against Mycobacterium sp. (especially M. tuberculosis) in association with other agents to overcome resistance - Staphylococcus - Neisseria meningitidis - Escherichia coli - Brucella Mechanism of action: - inhibits prokaryotic DNA-dependent RNA synthesis & protein synthesis - blocks RNA-polymerase transcription initiation Notes: - rifampin & rifabutin are related

Interactions

drug interactions

Specific

rifabutin (Mycobutin) rifampin; rifampicin (Rifadin, Rimactane) rifapentine (Priftin) rifaximin (Xifaxan, Fatroximin, Normix)

General

anti-tuberculous agent heterocyclic compound, 3 rings

Database Correlations

PUBCHEM correlations

References

  1. PubChem: 6324616
  2. WD: Rifamycin http://www.wrongdiagnosis.com/medical/rifamycin.htm
  3. Medic8: Rifamycin http://www.medic8.com/medicines/Rifamycin.html
  4. Chen LF, Kaye D. Current use for old antibacterial agents: polymyxins, rifamycins, and aminoglycosides. Infect Dis Clin North Am. 2009 Dec;23(4):1053-75, PMID: 19909897
  5. FDA News Release. Noove 16, 2018 FDA approves new drug to treat travelers' diarrhea. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm626121.htm